Recently, the "3rd Cancer Black Technology Annual Conference" was successfully held at the Hilton Shanghai Hongqiao Xiangyuan Hotel, and Suzhou Xinxie Biotechnology Co., Ltd. won the honor of "Top Ten Cancer Black Technology" at the annual meeting with SophCyte™ Kunlun automatic cell preparation all-in-one machine, and was recognized by the industry.
The "3rd Cancer Black Technology Annual Conference" is jointly sponsored by Beijing Heesco Clinical Oncology Research Foundation, Good Medical Exchange and Research Value Circle, aiming to provide a convenient communication platform for experts, scholars and innovative enterprises in the tumor medical ecology and link industrial ecological resources. The conference brought together more than 40 heavy guests and more than 80 cancer diagnosis and treatment enterprises, including Professor Rao Liao from the School of Pharmacy of Tsinghua University, Professor Wang Haopeng from the School of Life and Sciences of ShanghaiTech University, and Professor Ding Kefeng from the Second Affiliated Hospital of Zhejiang University School of Medicine.
At this conference, our SophCyte™ Kunlun automatic cell preparation integrated machine won the "Top Ten Tumor Black Technology" award at the annual meeting. As an independent cell preparation product under Xinxie Biotechnology, SophCyte™ Kunlun has been praised by the industry for its many advantages such as functional integration, equipment localization, and cell quality stability, and this award has strengthened the company's determination to research and develop scientific and technological innovation.
At the award ceremony, Dr. Chi Shen, CTO of Xinxie Biologics, said: "It is a great honor to receive the honor of 'Top Ten Cancer Black Technology'. This is a recognition of the continuous efforts and excellence of our company and team, as well as SophCyte™ Kunlun's automated cell preparation. We will continue to devote ourselves to innovative design and technology research and development in the field of CGT, and provide automated, customized and integrated overall solution services for global life sciences."
Xinxie Biotechnology
Founded in 2021, Suzhou Xinxie Biotechnology Co., Ltd. (hereinafter referred to as Xinxie Biotechnology) focuses on scientific and technological research and development in the field of cell and gene therapy (CGT), and wholeheartedly provides automated, customized and integrated overall solution services for global life sciences.
Since its establishment, the company has taken "protecting life and health with science and technology" as its mission, focused on the integration of research, production and marketing and localization in the field of CGT, and prepared to build nearly 5,000 square meters of office R&D laboratories and GMP-level clean workshops, including cell technology, flow cytometry analysis and molecular biology and other functional laboratories; The R&D products have also covered 10,000 types of equipment, reagents and consumables in the field, and have passed the ISO9001 quality management system certification, with the production qualification of Class I medical devices, Class II and Class III medical device business qualifications, etc., which fully guarantees the stability and data traceability of products.
In order to better promote the transformation, output and landing of R&D results, Xinxie Biotech has successively opened an operation center in Shanghai and offices in Guangzhou, Nanjing, Hangzhou and other places relying on its R&D strength in Suzhou; Based in East China, radiating the whole country, empowering the quality upgrade of industry products and helping the high-quality development of the CGT field in mainland China.